Ivarmacitinib Eased Refractory PCA: Case Report - Top_Thought_Leaders - MDSpire

Ivarmacitinib Eased Refractory PCA: Case Report

Off-label ivarmacitinib rapidly relieved pruritus and improved skin lesions in a patient with refractory primary cutaneous amyloidosis, according to a case report.

  • By

  • Andrea Surnit

  • May 20, 2026

  • 4 min

Share

Top Thought Leaders in Dermatology

Brief introduction explaining scope and methodology.

Original Source(s)

Ivarmacitinib Eased Refractory PCA: Case Report

  • by Andrea Surnit

  • May 20, 2026

Related Content

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.

Why FDA Said No to a Melanoma Drug

Questions over trial design and political pressure shadowed the rejection of Replimune’s RP1 treatment.

Guselkumab Shows Psoriasis Benefit in Darker Skin Tones

Randomized trial suggests sustained clearance across darker skin tones.